FDA Places Gene Therapy LX1001 on Fast Track

FDA Places Gene Therapy LX1001 on Fast Track

293421

FDA Places Gene Therapy LX1001 on Fast Track

LX1001, a gene therapy for Alzheimer’s disease being developed by Lexeo Therapeutics, has been granted fast track designation by the U.S. Food and Drug Administration (FDA). The therapy is designed to deliver a version of the APOE gene, called APOE2, to cells in the central nervous system (the brain and spinal cord) using an engineered viral vector. Every person inherits two copies of the APOE gene, one from each biological parent. There are three versions of…

You must be logged in to read/download the full post.